Rockefeller Capital Management
CVKD icon

Rockefeller Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Rockefeller Capital Management’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$768 Sell
150
-150
-50% -$1.05K ﹤0.01% 4522
2025
Q4 		$2.03K Hold
300
– – ﹤0.01% 4312
2025
Q3 		$4.15K Buy
+300
New +$3.71K ﹤0.01% 3925

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rockefeller Capital Management's CVKD Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Cadrenal Therapeutics (CVKD) stake by 50% in Q1 2026, selling an estimated $1.05K and leaving 150 shares worth $768. The position accounts for ﹤0.01% of the portfolio, ranked #4522.

Rockefeller Capital Management first reported a position in CVKD in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.15K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Rockefeller Capital Management held 150 shares of Cadrenal Therapeutics worth $768 as of Q1 2026.
  • Rockefeller Capital Management sold 150 Cadrenal Therapeutics shares in Q1 2026, an estimated $1.05K.
  • Cadrenal Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4522 holding.
  • Rockefeller Capital Management first reported a position in Cadrenal Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Cadrenal Therapeutics position peaked at $4.15K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.